featured
Gemcitabine Plus Erlotinib No Better Than Gemcitabine Alone in Patients After R0 Resection of Pancreatic Cancer
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
Journal of Clinical Oncology
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
CONKO-005: Adjuvant Chemotherapy With Gemcitabine Plus Erlotinib Versus Gemcitabine Alone in Patients After R0 Resection of Pancreatic Cancer: A Multicenter Randomized Phase III Trial
J. Clin. Oncol 2017 Aug 17;[EPub Ahead of Print], M Sinn, M Bahra, T Liersch, K Gellert, H Messmann, W Bechstein, D Waldschmidt, L Jacobasch, M Wilhelm, BM Rau, R Grützmann, A Weinmann, G Maschmeyer, U Pelzer, JM Stieler, JK Striefler, M Ghadimi, S Bischoff, B Dörken, H Oettle, H RiessFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.